Daniel D. Karp
Impact in
- Oncology top 0.5%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 85
- Colorectal Cancer Treatments and Studies 17
- Cancer Immunotherapy and Biomarkers 12
- Lung Cancer Research Studies 11
- Cancer Treatment and Pharmacology 11
-
- Lung Cancer Treatments and Mutations 37
- Co-authors
- Philip Bonomi (4 shared papers)Mark S. Huberman (4 shared papers)P. Santabárbara (2 shared papers)David S. Hong (91 shared papers)Román Pérez-Soler (2 shared papers)Eric K. Rowinsky (2 shared papers)James R. Rigas (2 shared papers)Lisa A. Hammond (2 shared papers)
- Journals
- Journal of Clinical Oncology (63 papers)Cancer (12 papers)Investigational New Drugs (9 papers)Cancer Research (9 papers)Annals of Oncology (8 papers)
- Partner nations
- United StatesChinaNetherlands
In The Last Decade
Daniel D. Karp
211 papers receiving 9.1k citations
Daniel D. Karp's Hit Papers
Peers
Comparison fields: 5 of 131
- Oncology 3.4k
- Pulmonary and Respiratory Medicine 3.0k
- Otorhinolaryngology 391
- Cancer Research 1.3k
- Biochemistry 248
Countries citing papers authored by Daniel D. Karp
This map shows the geographic impact of Daniel D. Karp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel D. Karp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel D. Karp more than expected).
Fields of papers citing papers by Daniel D. Karp
This network shows the impact of papers produced by Daniel D. Karp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel D. Karp. The network helps show where Daniel D. Karp may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel D. Karp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 218 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Hit paper breakdown → | 2000 | 1123 |
| 2 | Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and Neck Hit paper breakdown → | 1990 | 1063 |
| 3 | Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer Hit paper breakdown → | 2004 | 893 |
| 4 | A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer Hit paper breakdown → | 2003 | 865 |
| 5 | 1993 | 298 | |
| 6 | 2016 | 254 | |
| 7 | 1993 | 228 | |
| 8 | 2001 | 213 | |
| 9 | 2005 | 171 | |
| 10 | 1996 | 159 | |
| 11 | Differentiation patterns in the blastic phase of chronic myeloid leukemia. | 1983 | 156 |
| 12 | 2016 | 155 | |
| 13 | 2016 | 154 | |
| 14 | 2014 | 125 | |
| 15 | 2000 | 125 | |
| 16 | 2019 | 111 | |
| 17 | Down-regulation and antiproliferative role of C/EBPalpha in lung cancer. | 2002 | 109 |
| 18 | 2010 | 99 | |
| 19 | 2009 | 90 | |
| 20 | 2013 | 84 |
About Daniel D. Karp
Daniel D. Karp is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 218 papers that have together received 9.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (37 papers), Cancer Genomics and Diagnostics (27 papers), Colorectal Cancer Treatments and Studies (17 papers), PI3K/AKT/mTOR signaling in cancer (13 papers), Cancer Immunotherapy and Biomarkers (12 papers), Cancer, Hypoxia, and Metabolism (11 papers), Lung Cancer Research Studies (11 papers) and Cancer Treatment and Pharmacology (11 papers). The work is most often cited by research in Oncology (3.4k citations), Pulmonary and Respiratory Medicine (3.0k citations), Otorhinolaryngology (391 citations), Cancer Research (1.3k citations) and Biochemistry (248 citations). Daniel D. Karp has collaborated with scholars based in United States, China and Netherlands. Frequent co-authors include Philip Bonomi, Mark S. Huberman, P. Santabárbara, David S. Hong, Román Pérez-Soler, Eric K. Rowinsky, James R. Rigas, Lisa A. Hammond, Abraham Chachoua and R. Lotan. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Investigational New Drugs, Cancer Research and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.